Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

Stopped Due to improvement in the Coronavirus Disease 2019 (COVID-19) pandemic and low subject accrual.

Conditions

• Coronavirus Disease 2019 (COVID-19)
• Acute Lung Injury
• Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Interventions

• DRUG: Dociparstat sodium
• DRUG: Placebo

Sponsor

Jazz Pharmaceuticals